Efficacy of durvalumab for early-stage triple-negative breast cancer examined by race
Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African American (AA) ...
Aug 19, 2022
0
5